MedTrace Logo

Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin

NCT04879953 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2021-05-11

No results posted yet for this study

Summary

Pressurised intraperitoneal aerosol chemotherapy is a new surgical technique, developed for the treatment of initially unresectable peritoneal carcinomatosis. The objective of this study was to compare the results of PIPAC associated with systemic chemotherapy with those of systemic chemotherapy alone in patients with gastric peritoneal carcinomatosis without metastasis other than peritoneal, and WHO performance status \<3.

Conditions

  • Carcinomatosis, Peritoneal

Interventions

DRUG

PIPAC with systemic chemotherapy

PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.

DRUG

Systemic chemotherapy alone

Intravenous chemotherapy

Sponsors & Collaborators

  • Association Francaise de Chirurgie

    lead OTHER

Principal Investigators

  • Catherine Arvieux · Grenoble Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-08-30
Completion
2020-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04879953 on ClinicalTrials.gov